Biosyntia is an industrial biotech company developing bio-based manufacturing processes with core capabilities within strain engineering and fermentation. The company was founded in 2012 by Hans Genee, Andreas Lausten and serial entrepreneur, DTU Professor Morten Sommer. Today, 15 scientists and business developers operate from Biosyntia’s lab and offices in Copenhagen, Denmark. Biosyntia develops microbes and processes at an unprecedented speed and efficiency by employing its Biosynthetic Selections™ technology which dramatically reduce the risk, cost and time for developing fermentation processes.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.